Cormedix Stock Alpha and Beta Analysis
| CRMD Stock | USD 10.47 0.09 0.87% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as CorMedix. It also helps investors analyze the systematic and unsystematic risks associated with investing in CorMedix over a specified time horizon. Remember, high CorMedix's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to CorMedix's market risk premium analysis include:
Beta 1.39 | Alpha 0.43 | Risk 5.51 | Sharpe Ratio 0.0938 | Expected Return 0.52 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
CorMedix |
CorMedix Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. CorMedix market risk premium is the additional return an investor will receive from holding CorMedix long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in CorMedix. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate CorMedix's performance over market.| α | 0.43 | β | 1.39 |
CorMedix expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of CorMedix's Buy-and-hold return. Our buy-and-hold chart shows how CorMedix performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.CorMedix Market Price Analysis
Market price analysis indicators help investors to evaluate how CorMedix stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading CorMedix shares will generate the highest return on investment. By understating and applying CorMedix stock market price indicators, traders can identify CorMedix position entry and exit signals to maximize returns.
CorMedix Return and Market Media
The median price of CorMedix for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 10.29 with a coefficient of variation of 12.81. The daily time series for the period is distributed with a sample standard deviation of 1.3, arithmetic mean of 10.13, and mean deviation of 1.03. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Is CorMedix Stock Outpacing Its Medical Peers This Year | 12/27/2024 |
2 | Disposition of 11844 shares by Zelnick Kaufman Beth of CorMedix at 8.22 subject to Rule 16b-3 | 01/02/2025 |
3 | Acquisition by Erin Mistry of 62500 shares of CorMedix subject to Rule 16b-3 | 01/06/2025 |
4 | CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update | 01/07/2025 |
5 | Disposition of 5790 shares by Hurlburt Elizabeth of CorMedix at 11.19 subject to Rule 16b-3 | 01/10/2025 |
6 | Heres Why Were Not Too Worried About CorMedixs Cash Burn Situation | 01/17/2025 |
7 | Were Hopeful That CorMedix Will Use Its Cash Wisely | 01/22/2025 |
8 | Rosalind Advisors, Inc. Expands Stake in InspireMD Inc. | 02/07/2025 |
9 | Disposition of tradable shares by Stewart Robert A of CorMedix subject to Rule 16b-3 | 02/14/2025 |
10 | Disposition of 6044 shares by Zelnick Kaufman Beth of CorMedix at 8.77 subject to Rule 16b-3 | 02/21/2025 |
11 | While shareholders of CorMedix are in the black over 1 year, those who bought a week ago arent so fortunate | 02/26/2025 |
12 | Acquisition by Duncan Gregory Scott of 25000 shares of CorMedix subject to Rule 16b-3 | 03/05/2025 |
13 | CorMedix Shares Down 7.4 percent Heres Why | 03/13/2025 |
14 | Acquisition by Todisco Joseph of 20000 shares of CorMedix at 3.82 subject to Rule 16b-3 | 03/14/2025 |
About CorMedix Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including CorMedix or other stocks. Alpha measures the amount that position in CorMedix has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 0.0202 | 0.0179 | Price To Sales Ratio | 3.0K | 1.6K |
CorMedix Upcoming Company Events
As portrayed in its financial statements, the presentation of CorMedix's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CorMedix's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of CorMedix's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of CorMedix. Please utilize our Beneish M Score to check the likelihood of CorMedix's management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with CorMedix
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out CorMedix Backtesting, CorMedix Valuation, CorMedix Correlation, CorMedix Hype Analysis, CorMedix Volatility, CorMedix History and analyze CorMedix Performance. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
CorMedix technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.